Baseline and 12-month follow-up clinical and biological characteristics of patients reaching ACR remission or not reaching remission at follow-up
| Characteristics | Baseline characteristics of patients achieving ACR remission (30 patients) | Baseline characteristics of patients not achieving ACR remission (91 patients) | Follow-up characteristics of patients achieving ACR remission (30 patients) | Follow-up characteristics of patients not achieving ACR remission (91 patients) |
|---|---|---|---|---|
| Age, years | 55.0±13.3 | 53.2±13.3 | – | – |
| Sex, no. F (%) | 20 (66.7%) | 72 (79.1%) | – | – |
| Disease duration, months | 3.8±2.4 | 6.4±3.6* | – | – |
| VERA, n (%) | 19 (63.3%) | 25 (27.5%)* | – | – |
| ACPA, U/ml | 105.5±175.1 | 59.1±48.1 | 61.2±45.2 | 39.8±35.8 |
| ACPA+, n (%) | 20 (66.7%) | 68 (74.7%) | 18 (62.1%) | 61 (67.0%) |
| RF-IgM, U/ml | 55.0±71.2 | 105.5±138.1 | 33.7±73.4 | 37.2±56.7 |
| RF-IgM+, n (%) | 19 (63.3%) | 63 (69.2%) | 7 (24.1%) | 31 (34.1%) |
| RF-IgA, U/ml | 130.2±121.0 | 188.8±237.6 | 41.2±54.3 | 48.9±14.8 |
| RF-IgA+, n (%) | 13 (43.3%) | 32 (37.6%) | 8 (27.6%) | 12 (13.3%) |
| ESR, mm/I° h | 34.7±24.3 | 38.0±24.3 | 10.3±7.3 | 17.5±15.3† |
| CRP, mg/litre | 19.8±23.7 | 22.9±31.5 | 2.6±5.4 | 4.8±6.6† |
| DAS44 | 3.2±0.7 | 3.4±0.9 | 0.8±0.3 | 2.0±0.8† |
| HAQ-DI | 1.0±0.6 | 1.3±0.8 | 0.1±0.2 | 0.5±0.5† |
| Erosives | 5 (16.7%) | 29 (31.9%) | 9 (30.0%) | 39 (42.9%) |
| Sharp erosion score | 1.8±0.8 | 2.6±2.5 | 1.6±0.7 | 2.7±2.5 |
| Larsen score | 3.2±1.8 | 4.2±3.0 | 2.7±1.7 | 4.2±3.0 |
Characteristics at baseline and after 12 months of patients reaching ACR remission or not reaching ACR remission after 12 months of follow-up. The values are indicated as the mean±SD.
↵* p<0.05 between baseline characteristics of patients achieving and not achieving ACR remission.
↵† p<0.05 between 12-month characteristics of patients achieving and not achieving ACR remission.
ACR, American College of Rheumatology; ACPA, anti-cyclic citrullinated peptide antibodies; CRP, C reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; RF, rheumatoid factor; VERA, very early rheumatoid arthritis.